Search
01/04/2022
Single-Center Experience with Trabectedin for the Treatment of Non-L-sarcomas
Serda, PC, Teres, R, Sebio, A, Bague, S, Orellana, R, Moreno, ME, Riba, M, Lopez-Pousa, A. Single-Center Experience with Trabectedin for the Treatment of Non-L-sarcomas. ADVANCES IN THERAPY. 2022; 39(4)DOI:10.1007/s12325-022-02051-2. PMID:35129790. IF:3.800(Q2/4D).
01/04/2022
Risk factors associated with emergency service re-visits in frailty diabetic patients who consult for hypoglycaemia
Mas Malagarriga N., Ruiz Ramos J., Juanes Borrego A.M., Agra Montava I., Vega Hanna L., López Vinardell L., Puig Campmany M., Mangues Bafalluy M.A.. Risk factors associated with emergency service re-visits in frailty diabetic patients who consult for hypoglycaemia. Medicina De Familia-Semergen. 2022; 48(3)DOI:10.1016/j.semerg.2021.09.011. PMID:34848135. IF:(Q/D).
01/04/2022
Clinical and molecular response to dasatinib in an adult patient with Penttinen syndrome
Iznardo, H, Bredrup, C, Bernal, S, Gladkauskas, T, Mascaro, JM, Roe, E, Baselga, E. Clinical and molecular response to dasatinib in an adult patient with Penttinen syndrome. AMERICAN JOURNAL OF MEDICAL GENETICS PART A. 2022; 188(4)DOI:10.1002/ajmg.a.62603. PMID:34894066. IF:2.000(Q3/8D).
01/04/2022
Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis
Blauvelt, A, Tsai, TF, Langley, RG, Miller, M, Shen, YK, You, Y, Yang, YW, Papp, KA, Puig, L. Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2022; 86(4)DOI:10.1016/j.jaad.2021.11.004. PMID:34798201. IF:13.800(Q1/1D).